Madrigal Pharmaceuticals (MDGL) Depreciation & Amortization (CF) (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Depreciation & Amortization (CF) of $381000.0 for Q2 2026, up 1.06% year-over-year from $377000.0 in Q2 2025, and down 1.3% quarter-over-quarter from $386000.0 in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $381000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 1.06% year-over-year to $381000.0; the TTM figure through Jun 2026 stood at $1.5 million (up 7.06% YoY), while the FY2025 annual figure was $1.5 million, up 37.41% from the prior year.
- Depreciation & Amortization (CF) declined to $381000.0 in Q2 2026 per MDGL's latest filing, from $386000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $392000.0 in Q4 2025 and bottomed at $107000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $242388.9 across 5 years, with a median of $217500.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) retreated 5.31% — and 2024, when it jumped 155.63%.
- Madrigal Pharmaceuticals' Depreciation & Amortization (CF) stood at $129000.0 in 2022, then climbed by 10.08% to $142000.0 in 2023, then surged by 155.63% to $363000.0 in 2024, then climbed by 7.99% to $392000.0 in 2025, then declined by 2.81% to $381000.0 in 2026.
- Business Quant data shows MDGL's Depreciation & Amortization (CF) at $381000.0 in Q2 2026, $386000.0 in Q1 2026, and $392000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Madrigal Pharmaceuticals | 15.72 Bn | 14.88 Bn | - | 381,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 381,000.00 |
| Mar 31, 2026 | 386,000.00 |
| Dec 31, 2025 | 392,000.00 |
| Sep 30, 2025 | 358,000.00 |
| Jun 30, 2025 | 377,000.00 |
| Mar 31, 2025 | 379,000.00 |
| Dec 31, 2024 | 363,000.00 |
| Sep 30, 2024 | 298,000.00 |
| Jun 30, 2024 | 267,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Dec 31, 2023 | 142,000.00 |
| Sep 30, 2023 | 135,000.00 |
| Jun 30, 2023 | 126,000.00 |
| Mar 31, 2023 | 124,000.00 |
| Dec 31, 2022 | 129,000.00 |
| Sep 30, 2022 | 121,000.00 |
| Jun 30, 2022 | 110,000.00 |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | 106,000.00 |
| Sep 30, 2021 | 97,000.00 |